Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
|Articles|May 15, 2023
Noid Factoid from Episode 15
Author(s)Madeline Colli, Megan L'Heureux
Don't miss this Noid Factoid from Nathan Johnson, PhD, the Co-Founder and CEO of VERNE Bioanalytics.
Advertisement
Listen as Nathan Johnson, PhD, Co-Founder and CEO of VERNE Bioanalytics., shares a quick Noid Factoid with us!
On this month’s episode, we are joined by Nathan Johnson, PhD, the Co-Founder and CEO of VERNE Bioanalytics. Join us as we discuss Nathan’s background, knowledge about cannabis genetics, some of the challenges related to hops latent viroid, and more.
Hear more of what Nathan has to say in the full Noid Knowledge podcast episode:
Advertisement
Related to this article
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!
Our top cannabis news topics this week: President Trump’s executive order on cannabis rescheduling, hemp regulation legislation, NY program using cannabis to reduce opioid use, cannabis genetics and cannabinoid profiles, and the latest cannabis research studies.
This month’s webinar explored published research studies on cannabis and its effect on opioids, substance use reduction, alcohol use, and autism symptoms.
President Trump signed an executive order directing federal agencies to reclassify cannabis from Schedule I to Schedule III controlled substances.
Zacariah Hildenbrand, PhD and Adam Jacques discuss how cannabis genetics affect cannabinoids.
A recent study found that medical cannabis may play a role in decreasing opioid use.
Advertisement
Advertisement